Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 · Journal of Clinical Oncology · 2,650 citations
https://doi.org/10.1200/jco.2014.57.9151
S
Stephen L. Chan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
729
Papers
36.4K
Citations
84
h-index
254
i10-index
Stephen L. Chan is an academic researcher from Chinese University of Hong Kong. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Cancer Immunotherapy and Biomarkers. The author has an h-index of 84, co-authored 620 publications.
ORCID: 0000-0001-8998-5480Papers by this author
worksCabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
2018 · New England Journal of Medicine · 2,276 citations
https://doi.org/10.1056/nejmoa1717002
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · The Lancet · 891 citations
https://doi.org/10.1016/s0140-6736(23)00727-4
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · The Lancet · 891 citations
https://doi.org/10.1016/s0140-6736(23)00727-4
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2023 · The Lancet · 590 citations
https://doi.org/10.1016/s0140-6736(23)00961-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat